The FDA has granted orphan designation to uniQure biopharma’s treatment of Fabry disease, according to a post to the agency’s website.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
- uniQure announces dosing of first patient in Phase I/IIa trial of AMT-191
- uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
- uniQure COO Pierre Caloz to depart
- uniQure anounces restructuring, expects to reduce headcount by 65%